查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602815

抗体药物复合体契约製造市场：按连接器、条件和最终用途分类 - 2025-2030 年全球预测

Antibody Drug Conjugates Contract Manufacturing Market by Linker (Cleavable, Non-cleavable), Condition (Breast Cancer, Lymphoma, Myeloma), End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

抗体药物复合体契约製造市场2023年估值为118.8亿美元，预计2024年将达到130.6亿美元，复合年增长率为11.82%，2030年将达到259亿美元，预计将达到9000万美元。

抗体药物复合体（ADC）是兼具单株抗体的标靶化能力和细胞毒性药物的抗癌能力的生物製药，由于契约製造可以在确保严格的品管的同时扩大生产规模，因此特别受欢迎。 ADC 市场需要强大的、有针对性的癌症治疗方法，同时对健康细胞的损害最小。应用扩展到各种癌症的治疗，包括固体癌和骨髓恶性肿瘤。最终用途范围主要包括专注于尖端癌症治疗的製药和生物技术公司。市场成长受到连接器技术进步、研发投资增加以及全球癌症发生率上升等因素的影响。政府的支持和扩大已通过核准的ADC 产品组合也正在推动市场发展势头。技术创新、拓展新兴市场以及共同开发具有更高功效和安全性的下一代 ADC 创造了潜在的商机。最大限度地利用这些机会的研究包括投资研究伙伴关係、扩大服务欠缺地区的製造能力以及开发具有成本效益的 ADC 变体以提高可及性。

主要市场统计
基准年[2023] 118.8亿美元
预测年份 [2024] 130.6亿美元
预测年份 [2030] 259.9亿美元
复合年增长率（%） 11.82%

阻碍市场成长的挑战包括高昂的开发成本、复杂的製造流程、监管障碍以及对先进专业知识的需求。此外，保持遵守严格的法律体制可能会占用集中资源。创新和研究将提高连接体的稳定性，优化有效负载设计以提高疗效，同时减少副作用，并开发新型生物标记主导的疗法以改善患者分层和治疗结果。市场本质上是竞争性的，主要参与者不断寻求透过产品创新和策略联盟来实现其产品的差异化。维持强大的管道并适应不断变化的法规对于成功至关重要。公司应监控技术进步和专利状况，并积极主动地发现新发现。这种谨慎的态度使我们能够预测行业变化，并在充满活力和高度专业化的领域中拥抱新机会。

市场动态：揭示快速发展的抗体药物复合体契约製造市场的关键市场洞察

抗体药物复合体的契约製造市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 生物製药公司外包增加
    • CMO 的快速增加和持续的研发活动
    • 慢性病增加导致 ADC 需求增加
  • 市场限制因素
    • 建立抗体药物复合体生产设施的成本高昂
  • 市场机会
    • ADC 的监管核准迅速增加
    • 扩大先进製造技术投资
  • 市场挑战
    • 对 CMO 的严格监管要求

波特五力：引领抗体药物复合体契约製造市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗体药物复合体契约製造市场的外部影响

外部宏观环境因素在塑造抗体药物复合体契约製造市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解抗体药物复合体契约製造市场的竞争状况

抗体药物复合体契约製造市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵抗体药物复合体契约製造市场供应商的绩效评估

FPNV定位矩阵是评估抗体药物复合体契约製造市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，描绘抗体药物复合体契约製造市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对抗体药物复合体契约製造市场进行策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 生物製药公司外包增加
      • CMO 数量和持续研发活动迅速增加
      • 由于慢性病的流行，对 ADC 的需求增加
    • 抑制因素
      • 建立抗体药物复合体生产设施的高成本
    • 机会
      • ADC 的监管核准迅速增加
      • 扩大先进製造技术投资
    • 任务
      • 对 CMO 的严格监管要求
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章抗体药物复合体契约製造市场链接

  • 可切割
  • 不可切割

第七章依现状分類的抗体药物复合体契约製造市场

  • 乳癌
  • 淋巴瘤
  • 骨髓瘤

第八章抗体药物复合体契约製造市场：依最终用途分类

  • 临床试验
  • 骨髓瘤治疗

第九章北美和南美抗体药物复合体契约製造市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太抗体药物复合体契约製造市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章：欧洲、中东和非洲抗体药物复合体的契约製造市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • ADC Therapeutics SA.
  • AstraZeneca PLC
  • Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories
  • Axplora
  • Catalent, Inc.
  • Creative Biolabs
  • Daiichi Sankyo
  • EirGenix, Inc.
  • Gilead Sciences
  • GlaxoSmithKline PLC
  • ImmunoGen, Inc.
  • Merck KgaA
  • Mersana Therapeutics
  • MicroBiopharm Japan Co., Ltd.
  • Pfizer Inc.
  • Pierre Fabre SA
  • Piramal Pharma Solutions
  • Recipharm AB
  • Regeneron Pharmaceuticals, Inc.
  • Samsung Biologics
  • Sanofi
  • Sartorius AG
Product Code: MRR-B16853777700

The Antibody Drug Conjugates Contract Manufacturing Market was valued at USD 11.88 billion in 2023, expected to reach USD 13.06 billion in 2024, and is projected to grow at a CAGR of 11.82%, to USD 25.99 billion by 2030.

Antibody Drug Conjugates (ADCs) are biopharmaceuticals that combine the targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, specifically versatile as contract manufacturing facilitates scaling up production while ensuring stringent quality controls. The ADC market is necessary due to its potent and targeted cancer therapies, minimizing damage to healthy cells. Its applications span various oncology treatments, including solid tumors and hematologic malignancies. The end-use scope primarily involves pharmaceutical companies and biotechnology firms focused on cutting-edge cancer treatments. Market growth is influenced by factors such as advancements in linker technology, increased R&D investments, and rising cancer prevalence globally. Government support and an expanding portfolio of approved ADCs also drive market momentum. Potential opportunities arise from technological innovations, expanding into emerging markets, and collaborating on next-generation ADCs with improved efficacy and safety profiles. Recommendations to maximize these opportunities include investing in research partnerships, expanding manufacturing capabilities in underserved regions, and developing cost-effective ADC variants to improve accessibility.

KEY MARKET STATISTICS
Base Year [2023] USD 11.88 billion
Estimated Year [2024] USD 13.06 billion
Forecast Year [2030] USD 25.99 billion
CAGR (%) 11.82%

Limitations challenging market growth include high developmental costs, complex manufacturing processes, regulatory hurdles, and the need for highly specialized expertise. Furthermore, maintaining adherence to stringent legal frameworks can be resource-intensive. Innovation and research can focus on improving linker stability, optimizing payload design to enhance efficacy while reducing side effects, and developing novel biomarker-driven therapies that improve patient stratification and treatment outcomes. The market is of competitive nature, with key players continuously seeking to differentiate their offerings through product innovation and strategic collaborations. Maintaining a robust pipeline and adaptability to evolving regulations will be crucial for success. Companies should monitor technological advances and patent landscapes, ensuring proactive engagement with new discoveries. This vigilant approach can anticipate industry shifts and embrace emerging opportunities in a dynamic and highly specialized field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibody Drug Conjugates Contract Manufacturing Market

The Antibody Drug Conjugates Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing outsourcing by biopharmaceutical companies
    • Surging number of CMOs and ongoing R&D activities
    • Growing demand for ADC amid high prevalence of chronic disease
  • Market Restraints
    • High cost of setting up a production facility for antibody-drug conjugates
  • Market Opportunities
    • Surge in ADC approvals from regulatory bodies
    • Expanding investments in advanced manufacturing technologies
  • Market Challenges
    • Stringent regulatory requirements for CMOs

Porter's Five Forces: A Strategic Tool for Navigating the Antibody Drug Conjugates Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibody Drug Conjugates Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibody Drug Conjugates Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibody Drug Conjugates Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibody Drug Conjugates Contract Manufacturing Market

A detailed market share analysis in the Antibody Drug Conjugates Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibody Drug Conjugates Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibody Drug Conjugates Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibody Drug Conjugates Contract Manufacturing Market

A strategic analysis of the Antibody Drug Conjugates Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibody Drug Conjugates Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., ADC Therapeutics SA., AstraZeneca PLC, Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories, Axplora, Catalent, Inc., Creative Biolabs, Daiichi Sankyo, EirGenix, Inc., Gilead Sciences, GlaxoSmithKline PLC, ImmunoGen, Inc., Merck KgaA, Mersana Therapeutics, MicroBiopharm Japan Co., Ltd., Pfizer Inc., Pierre Fabre S.A, Piramal Pharma Solutions, Recipharm AB, Regeneron Pharmaceuticals, Inc., Samsung Biologics, Sanofi, and Sartorius AG.

Market Segmentation & Coverage

This research report categorizes the Antibody Drug Conjugates Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Linker, market is studied across Cleavable and Non-cleavable.
  • Based on Condition, market is studied across Breast Cancer, Lymphoma, and Myeloma.
  • Based on End Use, market is studied across Clinical Trial and Myeloma Treatment.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing outsourcing by biopharmaceutical companies
      • 5.1.1.2. Surging number of CMOs and ongoing R&D activities
      • 5.1.1.3. Growing demand for ADC amid high prevalence of chronic disease
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of setting up a production facility for antibody-drug conjugates
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in ADC approvals from regulatory bodies
      • 5.1.3.2. Expanding investments in advanced manufacturing technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements for CMOs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibody Drug Conjugates Contract Manufacturing Market, by Linker

  • 6.1. Introduction
  • 6.2. Cleavable
  • 6.3. Non-cleavable

7. Antibody Drug Conjugates Contract Manufacturing Market, by Condition

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Lymphoma
  • 7.4. Myeloma

8. Antibody Drug Conjugates Contract Manufacturing Market, by End Use

  • 8.1. Introduction
  • 8.2. Clinical Trial
  • 8.3. Myeloma Treatment

9. Americas Antibody Drug Conjugates Contract Manufacturing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. ADC Therapeutics SA.
  • 3. AstraZeneca PLC
  • 4. Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories
  • 5. Axplora
  • 6. Catalent, Inc.
  • 7. Creative Biolabs
  • 8. Daiichi Sankyo
  • 9. EirGenix, Inc.
  • 10. Gilead Sciences
  • 11. GlaxoSmithKline PLC
  • 12. ImmunoGen, Inc.
  • 13. Merck KgaA
  • 14. Mersana Therapeutics
  • 15. MicroBiopharm Japan Co., Ltd.
  • 16. Pfizer Inc.
  • 17. Pierre Fabre S.A
  • 18. Piramal Pharma Solutions
  • 19. Recipharm AB
  • 20. Regeneron Pharmaceuticals, Inc.
  • 21. Samsung Biologics
  • 22. Sanofi
  • 23. Sartorius AG

LIST OF FIGURES

  • FIGURE 1. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MYELOMA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 144. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023